No material signal from this cluster. The small dollar amounts and concurrent option exercises suggest routine tax-related selling. Monitor for larger insider transactions (>0.5% of market cap) or a cluster of open-market purchases for a directional read.
NRIX drugs
NRIX drug pipeline →- ▲ bexobrutideg 5/10 Phase 1a/b (pivotal Phase 2 underway; Phase 3 planned summer 2026)
- ● GS-6791 4/10 Phase 1
- ● NX-1607 4/10 Phase 1 (Phase 1a dose escalation complete; Phase 1b expansion planned)
- ● zelebrudomide 3/10 Phase 1
- ● NX-3911 2/10 Preclinical / IND-enabling — Phase 1 trial authorized (EU CTIS) but not yet recruiting
- All NRIX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 3 $25.32entry
- T+1 · 2mo ago +3.24%α +3.62% · $26.14
- T+5 · 2mo ago −0.87%α +0.28% · $25.10
- T+20 · 7w ago −9.20%α −8.01% · $22.99
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
How similar events traded
Executive Summary
Two C-suite insiders at Nurix Therapeutics (NRIX), Chief Scientific Officer Gwenn Hansen and Chief Legal Officer Christine Ring, sold a combined $175K in open-market transactions over a 2-day window. The total represents ~0.0065% of the company's $2.7B market cap, making the cluster economically trivial and likely driven by routine tax withholding or option-exercise-related sales.
Key Financial Metrics
Key Facts
- Chief Scientific Officer Gwenn Hansen sold 1,452 shares at $25.47 for $36,982 on 2026-09-01.
- Chief Legal Officer Christine Ring sold 5,787 shares at $25.69 for $138,417 on 2026-09-02 (includes 400 shares at $26.64).
- Both insiders also exercised derivative securities (non-cash) on the same dates, consistent with option-exercise-and-sell patterns.
- Total insider sales of $175K represent ~0.0065% of NRIX's $2.7B market cap, well below the 0.1% materiality threshold.
Financial Impact
Two C-suite insiders sold $175K total, representing ~0.0065% of market cap, trivial and non-material.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NRIX-1788392609018 |
Track record
33 reports on NRIX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
- Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
- Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers